{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:47:16Z","timestamp":1760230036994,"version":"build-2065373602"},"reference-count":53,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31900490"],"award-info":[{"award-number":["31900490"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Symmetry"],"abstract":"<jats:p>High-grade serous ovarian carcinoma (HGSC), the most common and aggressive histological type of ovarian cancer, remains the leading cause of cancer-related deaths among females. It is important to develop novel drugs to improve the therapeutic outcomes of HGSC patients, thereby reducing their mortality. Symmetry is one of the most important properties of the biological network, which determines the stability of a biological system. As aberrant gene expression is a critical symmetry-breaking event that perturbs the stability of biological networks and triggers tumor progression, we aim in this study to discover new candidate drugs and predict their targets for HGSC therapy based on differentially expressed genes involved in HGSC pathogenesis. Firstly, 98 up-regulated genes and 108 down-regulated genes were identified from three independent transcriptome datasets. Then, the small-molecule compounds PHA-793887, pidorubicine and lestaurtinib, which target cell-cycle-related processes, were identified as novel candidate drugs for HGSC treatment by adopting the connectivity map (CMap)-based drug repositioning approach. Furthermore, through a topological analysis of the protein\u2013protein interaction network, cell cycle regulators CDK1, TOP2A and AURKA were identified as bottleneck nodes, and their expression patterns were validated at the mRNA and protein expression levels. Moreover, the results of molecular docking analysis showed that PHA-793887, pidorubicine and lestaurtinib had a strong binding affinity for CDK1, TOP2A and AURKA, respectively. Therefore, our study repositioned PHA-793887, pidorubicine and lestaurtinib, which can inhibit cell cycle regulators, as novel agents for HGSC treatment, thereby helping to optimize the therapeutic strategy for HGSC.<\/jats:p>","DOI":"10.3390\/sym14071403","type":"journal-article","created":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:06:21Z","timestamp":1657497981000},"page":"1403","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Identification of Novel Drugs Targeting Cell Cycle Regulators for the Treatment of High-Grade Serous Ovarian Cancer via Integrated Bioinformatics Analysis"],"prefix":"10.3390","volume":"14","author":[{"given":"Yuanchun","family":"Zhao","sequence":"first","affiliation":[{"name":"School of Chemistry and Life Sciences, Suzhou University of Science and Technology, Suzhou 215011, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiachen","family":"Zuo","sequence":"additional","affiliation":[{"name":"School of Chemistry and Life Sciences, Suzhou University of Science and Technology, Suzhou 215011, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2558-815X","authenticated-orcid":false,"given":"Yiming","family":"Shen","sequence":"additional","affiliation":[{"name":"School of Chemistry and Life Sciences, Suzhou University of Science and Technology, Suzhou 215011, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghui","family":"Yan","sequence":"additional","affiliation":[{"name":"School of Chemistry and Life Sciences, Suzhou University of Science and Technology, Suzhou 215011, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajia","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Chemistry and Life Sciences, Suzhou University of Science and Technology, Suzhou 215011, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Qi","sequence":"additional","affiliation":[{"name":"School of Chemistry and Life Sciences, Suzhou University of Science and Technology, Suzhou 215011, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Sah, S., Ma, X., Botros, A., Gaul, D.A., Yun, S.R., Park, E.Y., Kim, O., Moore, S.G., Kim, J., and Fernandez, F.M. (2022). Space- and Time-Resolved Metabolomics of a High-Grade Serous Ovarian Cancer Mouse Model. Cancers, 14.","DOI":"10.3390\/cancers14092262"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"108276","DOI":"10.1016\/j.celrep.2020.108276","article-title":"Integrated Proteomic and Glycoproteomic Characterization of Human High-Grade Serous Ovarian Carcinoma","volume":"33","author":"Hu","year":"2020","journal-title":"Cell Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/bib\/bbv020","article-title":"A survey of current trends in computational drug repositioning","volume":"17","author":"Li","year":"2016","journal-title":"Brief. Bioinform."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1126\/science.1132939","article-title":"The Connectivity Map: Using gene-expression signatures to connect small molecules, genes, and disease","volume":"313","author":"Lamb","year":"2006","journal-title":"Science"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","article-title":"A next generation connectivity map: L1000 platform and the first 1,000,000 profiles","volume":"171","author":"Subramanian","year":"2017","journal-title":"Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.gene.2018.09.040","article-title":"Weighted gene co-expression network analysis and connectivity map identifies lovastatin as a treatment option of gastric cancer by inhibiting HDAC2","volume":"681","author":"Zhang","year":"2019","journal-title":"Gene"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"745590","DOI":"10.3389\/fonc.2021.745590","article-title":"Identification of Novel Drug Candidate for Epithelial Ovarian Cancer via In Silico Investigation and In Vitro Validation","volume":"11","author":"Zou","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_9","first-page":"1","article-title":"KLF7: A new candidate biomarker and therapeutic target for high-grade serous ovarian cancer","volume":"39","author":"Babini","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"10047s1","DOI":"10.1016\/j.xcrm.2021.100471","article-title":"Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer","volume":"2","author":"Huang","year":"2021","journal-title":"Cell Rep. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s11224-007-9212-8","article-title":"Symmetry breaking in biological systems. From molecules to tissues","volume":"18","author":"Robert","year":"2007","journal-title":"Struct. Chem."},{"key":"ref_12","first-page":"17","article-title":"Protein-protein interaction networks (PPI) and complex diseases","volume":"7","author":"Taghizadeh","year":"2014","journal-title":"Gastroenterol. Hepatol. Bed Bench"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2174\/138920021801170119204832","article-title":"Protein-protein interaction (PPI) network: Recent advances in drug discovery","volume":"18","author":"Athanasios","year":"2017","journal-title":"Curr. Drug Metab."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Nithya, C., Kiran, M., and Nagarajaram, H.A. (2021). Comparative analysis of Pure Hubs and Pure Bottlenecks in Human Protein-protein Interaction Networks. bioRxiv.","DOI":"10.1101\/2021.04.06.438602"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5478","DOI":"10.1158\/0008-5472.CAN-07-6595","article-title":"A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer","volume":"68","author":"Bonome","year":"2008","journal-title":"Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ccr.2009.10.018","article-title":"A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: Microfibril-associated glycoprotein 2","volume":"16","author":"Mok","year":"2009","journal-title":"Cancer Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1158\/1078-0432.CCR-07-4959","article-title":"Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma","volume":"14","author":"Tone","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"ref_19","first-page":"100141","article-title":"clusterProfiler 4.0: A universal enrichment tool for interpreting omics data","volume":"2","author":"Wu","year":"2021","journal-title":"Innovation"},{"key":"ref_20","first-page":"506","article-title":"A review of connectivity map and computational approaches in pharmacogenomics","volume":"19","author":"Musa","year":"2018","journal-title":"Brief. Bioinform."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"D605","DOI":"10.1093\/nar\/gkaa1074","article-title":"The STRING database in 2021: Customizable protein\u2013protein networks, and functional characterization of user-uploaded gene\/measurement sets","volume":"49","author":"Szklarczyk","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Kohl, M., Wiese, S., and Warscheid, B. (2011). Cytoscape: Software for visualization and analysis of biological networks. Data Mining in Proteomics, Humana Press.","DOI":"10.1007\/978-1-60761-987-1_18"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2105-12-77","article-title":"pROC: An open-source package for R and S+ to analyze and compare ROC curves","volume":"12","author":"Robin","year":"2011","journal-title":"BMC Bioinform."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e27633","DOI":"10.2196\/27633","article-title":"Web-based survival analysis tool tailored for medical research (KMplot): Development and implementation","volume":"23","year":"2021","journal-title":"J. Med. Internet Res."},{"key":"ref_25","first-page":"D271","article-title":"The RCSB protein data bank: Integrative view of protein, gene and 3D structural information","volume":"45","author":"Rose","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1758-2946-3-12","article-title":"Multilevel parallelization of AutoDock 4.2","volume":"3","author":"Norgan","year":"2011","journal-title":"J. Cheminform."},{"key":"ref_27","first-page":"82","article-title":"Pymol: An open-source molecular graphics tool. CCP4 Newsl","volume":"40","author":"DeLano","year":"2002","journal-title":"Protein Crystallogr."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"W98","DOI":"10.1093\/nar\/gkx247","article-title":"GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses","volume":"45","author":"Tang","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1260419","DOI":"10.1126\/science.1260419","article-title":"Tissue-based map of the human proteome","volume":"347","author":"Fagerberg","year":"2015","journal-title":"Science"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41467-017-00962-1","article-title":"High grade serous ovarian carcinomas originate in the fallopian tube","volume":"8","author":"Papp","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.drudis.2012.07.017","article-title":"Applications of Connectivity Map in drug discovery and development","volume":"17","author":"Qu","year":"2012","journal-title":"Drug Discov. Today"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/0090-8258(92)90261-G","article-title":"Phase II trial of amonafide in previously treated patients with advanced ovarian cancer: A Southwest Oncology Group study","volume":"46","author":"Gallion","year":"1992","journal-title":"Gynecol. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"100626","DOI":"10.1016\/j.gore.2020.100626","article-title":"Palbociclib in the treatment of recurrent ovarian cancer","volume":"34","author":"Ho","year":"2020","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ygyno.2008.01.009","article-title":"A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study","volume":"109","author":"Modesitt","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1002\/1097-0142(19851215)56:12<2756::AID-CNCR2820561206>3.0.CO;2-6","article-title":"Treatment of malignant nondysgerminomatous germ cell tumors of the ovary with vincristine, dactinomycin, and cyclophosphamide","volume":"56","author":"Gershenson","year":"1985","journal-title":"Cancer"},{"key":"ref_36","first-page":"301","article-title":"Apicidin, a novel histone deacetylase inhibitor, has profound anti-growth activity in human endometrial and ovarian cancer cells","volume":"19","author":"Ueda","year":"2007","journal-title":"Int. J. Mol. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/path.3022","article-title":"The cell cycle and cancer","volume":"226","author":"Williams","year":"2012","journal-title":"J. Pathol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"9408","DOI":"10.1200\/JCO.2005.01.5594","article-title":"Targeting the cell cycle: A new approach to cancer therapy","volume":"23","author":"Schwartz","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1016\/j.bmcl.2015.05.100","article-title":"Cyclin dependent kinase (CDK) inhibitors as anticancer drugs","volume":"25","author":"Gelbert","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3109\/14756366.2012.658785","article-title":"Topoisomerase as target for antibacterial and anticancer drug discovery","volume":"28","author":"Kathiravan","year":"2013","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"16425","DOI":"10.18632\/aging.203165","article-title":"Selected using bioinformatics and molecular docking analyses, PHA-793887 is effective against osteosarcoma","volume":"13","author":"Wu","year":"2021","journal-title":"Aging"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2174\/2212697X08666210219101023","article-title":"The Antimalarial Drug Pyronaridine Inhibits Topoisomerase II in Breast Cancer Cells and Hinders Tumor Progression In Vivo","volume":"8","author":"Villanueva","year":"2021","journal-title":"Clin. Cancer Drugs"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/s41375-021-01177-6","article-title":"FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children\u2019s Oncology Group trial AALL0631","volume":"35","author":"Brown","year":"2021","journal-title":"Leukemia"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.bmc.2010.01.042","article-title":"Optimization of 6, 6-dimethyl pyrrolo [3, 4-c] pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing","volume":"18","author":"Brasca","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa052084","article-title":"Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer","volume":"355","author":"Poole","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1517\/13543781003598862","article-title":"Lestaurtinib, a multitargeted tyrosinse kinase inhibitor: From bench to bedside","volume":"19","author":"Shabbir","year":"2010","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s00280-011-1581-4","article-title":"Phase I trial of lestaurtinib for children with refractory neuroblastoma: A new approaches to neuroblastoma therapy consortium study","volume":"68","author":"Minturn","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"165715","DOI":"10.1016\/j.bbadis.2020.165715","article-title":"Cell cycle regulators in cancer cell metabolism","volume":"1866","author":"Fajas","year":"2020","journal-title":"Biochim. Biophys. Acta (BBA)-Mol. Basis Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.7150\/jca.42736","article-title":"TOP2A promotes tumorigenesis of high-grade serous ovarian cancer by regulating the TGF-\u03b2\/Smad pathway","volume":"11","author":"Gao","year":"2020","journal-title":"J. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12943-020-01305-3","article-title":"Targeting AURKA in Cancer: Molecular mechanisms and opportunities for Cancer therapy","volume":"20","author":"Du","year":"2021","journal-title":"Mol. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.chembiol.2018.10.015","article-title":"Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition","volume":"26","author":"Wood","year":"2019","journal-title":"Cell Chem. Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"37041","DOI":"10.1074\/jbc.M506520200","article-title":"Nucleotide-dependent domain movement in the ATPase domain of a human type IIA DNA topoisomerase","volume":"280","author":"Wei","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1158\/2159-8290.CD-18-0469","article-title":"Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene","volume":"9","author":"Gong","year":"2019","journal-title":"Cancer Discov."}],"container-title":["Symmetry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-8994\/14\/7\/1403\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:44:14Z","timestamp":1760139854000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-8994\/14\/7\/1403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,8]]},"references-count":53,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["sym14071403"],"URL":"https:\/\/doi.org\/10.3390\/sym14071403","relation":{},"ISSN":["2073-8994"],"issn-type":[{"type":"electronic","value":"2073-8994"}],"subject":[],"published":{"date-parts":[[2022,7,8]]}}}